JERUSALEM--(BUSINESS WIRE)-- BioLineRx Ltd. (TASE:BLRX), Israel’s leading drug development company, announced today the successful completion of a study determining the clinical binding properties of BL-1020 to the dopamine receptors in the human brain. The study has shown that BL-1020, the first GABA enhanced antipsychotic clinical candidate for the treatment of schizophrenia, blocks dopamine receptors in the human brain, providing direct evidence of antipsychotic efficacy. The study further supports the safety of BL-1020. In addition, this study provides evidence that the 32 mg will be clinically efficacious and that BL-1020 can be given once daily.
